Results of the 67th American Society of Hematology (ASH 2025) Annual Meeting: Their Importance for Practical Hematology

Aleksander Sergeevich Luchinin,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-2-conference
Results of the 67th American Society of Hematology (ASH 2025) Annual Meeting: Their Importance for Practical Hematology
  1. Mateos M-V, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. Blood. 2025;146(Suppl 2):LBA-6. doi: 10.1182/blood-2025-LBA-6. DOI: https://doi.org/10.1182/blood-2025-LBA-6
  2. Mateos M-V, Magen H, Gatt M, et al. Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years. Blood. 2025;146(Suppl 1):701. doi: 10.1182/blood-2025-701. DOI: https://doi.org/10.1182/blood-2025-701
  3. Dytfeld D, Kubicki T, Tyczynska A, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) — interim results from the randomized Phase III COBRA trial. Blood. 2025;146(Suppl 1):99. doi: 10.1182/blood-2025-99. DOI: https://doi.org/10.1182/blood-2025-99
  4. Suvannasankha A, Kaufman J, Badros A, et al. Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial. Blood. 2025;146(Suppl 1):100. doi: 10.1182/blood-2025-100. DOI: https://doi.org/10.1182/blood-2025-100
  5. Harrison S, Ho PJ, Lim S-L, et al. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. 2025;146(Suppl 2):LBA-1. doi: 10.1182/blood-2025-LBA-1. DOI: https://doi.org/10.1182/blood-2025-LBA-1
  6. Lee H, Ahn S, Vishwamitra D, et al. Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers. Blood. 2025;146(Suppl 1):1030. doi: 10.1182/blood-2025-1030. DOI: https://doi.org/10.1182/blood-2025-1030
  7. Mateos M-V, Martinez-Lopez J, González-Calle V, et al. Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)-autologous stem cell transplantation (ASCT)-krd-rd. Blood. 2025;146(Suppl 1):371. doi: 10.1182/blood-2025-371. DOI: https://doi.org/10.1182/blood-2025-371
  8. Voorhees P, Dimopoulos M, Cohen Y, et al. Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age. Blood. 2025;146(Suppl 1):372. doi: 10.1182/blood-2025-372. DOI: https://doi.org/10.1182/blood-2025-372
  9. Zhang Q, Jiang S, Liu Y, et al. The phase II study of zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL) patients with specific gene-expression. Blood. 2025;146(Suppl 1):57. doi: 10.1182/blood-2025-57. DOI: https://doi.org/10.1182/blood-2025-57
  10. Westin J, Fayad L, Steiner R, et al. primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma. Blood. 2025;146(Suppl 1):477. doi: 10.1182/blood-2025-477. DOI: https://doi.org/10.1182/blood-2025-477
  11. Reagan P, Shamas N, Masaquel A, et al. Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US). Blood. 2025;146(Suppl 1):6265. doi: 10.1182/blood-2025-6265. DOI: https://doi.org/10.1182/blood-2025-6265
  12. Huebel K, Strati P, Sehn L, et al. Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients. Blood. 2025;146(Suppl 1):5367. doi: 10.1182/blood-2025-5367. DOI: https://doi.org/10.1182/blood-2025-5367
  13. Falchi L, Nijland M, Huang H, et al. primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma. Blood. 2025;146(Suppl 1):466. doi: 10.1182/blood-2025-466. DOI: https://doi.org/10.1182/blood-2025-466
  14. Falchi L, Grieve C, Miah C, et al. Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial. Blood. 2025;146(Suppl 1):463. doi: 10.1182/blood-2025-463. DOI: https://doi.org/10.1182/blood-2025-463
  15. Ansari S, Kamdar M, Papp E, et al. INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile. Blood. 2025;146(Suppl 1):1775. doi: 10.1182/blood-2025-1775. DOI: https://doi.org/10.1182/blood-2025-1775
  16. Schuster S, Thieblemont C, Dickinson M, et al. Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update. Blood. 2025;146(Suppl 1):468. doi: 10.1182/blood-2025-468. DOI: https://doi.org/10.1182/blood-2025-468
  17. Khwaja J, Kirkwood A, Milani P, et al. A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era. Blood. 2025;146(Suppl 1):577. doi: 10.1182/blood-2025-577. DOI: https://doi.org/10.1182/blood-2025-577
  18. Herrera A, Leblanc M, Castellino S, et al. 3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma. Blood. 2025;146(Suppl 1):151. doi: 10.1182/blood-2025-151. DOI: https://doi.org/10.1182/blood-2025-151
  19. Maurer MJ, Parsons SK, Upshaw JN, et al. The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool. Blood Adv. 2025;9(6):1366–9. doi: 10.1182/bloodadvances.2024014689. DOI: https://doi.org/10.1182/bloodadvances.2024014689
  20. Ferdinandus J, Kaul H, Moccia A, et al. Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma. Blood. 2025;146(Suppl 1):152. doi: 10.1182/blood-2025-152. DOI: https://doi.org/10.1182/blood-2025-152
  21. Jurczak W, Kwiatek M, Czyz J, et al. Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients. Blood. 2025;146(Suppl 2):LBA-3. doi: 10.1182/blood-2025-LBA-3. DOI: https://doi.org/10.1182/blood-2025-LBA-3
  22. Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial. Blood. 2025;146(Suppl 1):1. doi: 10.1182/blood-2025-1. DOI: https://doi.org/10.1182/blood-2025-1
  23. Wang M, Cohen J, Shah N, et al. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study. Blood. 2025;146(Suppl 1):665. doi: 10.1182/blood-2025-665. DOI: https://doi.org/10.1182/blood-2025-665
  24. Wang Y, Larson MC, Hwang SR, et al. Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma. Blood Adv. 2025:bloodadvances.2025018527. doi: 10.1182/bloodadvances.2025018527. DOI: https://doi.org/10.1182/bloodadvances.2025018527
  25. Healton S, Soumerai J, Barnes J, et al. Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD. Blood. 2025;146(Suppl 1):3569. doi: 10.1182/blood-2025-3569. DOI: https://doi.org/10.1182/blood-2025-3569
  26. Wang M, Paludo J, de Holanda Farias JS, et al. Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up. Blood. 2025;146(Suppl 1):885. doi: 10.1182/blood-2025-885. DOI: https://doi.org/10.1182/blood-2025-885
  27. Hawkes E, Romejko-Jarosinska J, Jurczak W, et al. Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study. Blood. 2025;146(Suppl 1):884. doi: 10.1182/blood-2025-884. DOI: https://doi.org/10.1182/blood-2025-884
  28. Dali SA, Al-Mashdali AF, Kalfah A, Mohamed SF. Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacy. Crit Rev Oncol Hematol. 2025;213:104783. doi: 10.1016/j.critrevonc.2025.104783. DOI: https://doi.org/10.1016/j.critrevonc.2025.104783
  29. Iqbal U, Chan O, Shallis R, et al. Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability. Blood. 2025;146(Suppl 1):3448. doi: 10.1182/blood-2025-3448. DOI: https://doi.org/10.1182/blood-2025-3448
  30. Jain J, Huang Y, Dvorak-Kornaus K, et al. Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement. Blood. 2025;146(Suppl 1):5211. doi: 10.1182/blood-2025-5211. DOI: https://doi.org/10.1182/blood-2025-5211
  31. Fathi A, Perl A, Fell G, et al. Results from paradigm — a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2025;146(Suppl 1):6. doi: 10.1182/blood-2025-6. DOI: https://doi.org/10.1182/blood-2025-6
  32. Al-Samkari H, Cuker A, Zaja F, et al. Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment. Blood. 2025;146(Suppl 2):LBA-2. doi: 10.1182/blood-2025-LBA-2. DOI: https://doi.org/10.1182/blood-2025-LBA-2

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Aleksander Sergeevich Luchinin, MD, PhD, NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522, e-mail: glivec@mail.ru
2026-2

Downloads

Published

01.04.2026

Issue

Vol. 19 No. 2 (2026)
CONGRESSES, CONFERENCES, SYMPOSIA

How to Cite

Luchinin A.S. Results of the 67th American Society of Hematology (ASH 2025) Annual Meeting: Their Importance for Practical Hematology. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(2):229–237. doi:10.21320/2500-2139-2026-19-2-conference.

Most read articles by the same author(s)